Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MV-RSV-01
- Development stage
- Unknown
- Lead developer
- MAXVAX Biotechnology
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MV-RSV-01 is a recombinant protein vaccine candidate developed by MAXVAX Biotechnology for the prevention of respiratory syncytial virus (RSV) infection and associated lower respiratory tract disease. The vaccine is produced using a Chinese Hamster Ovary (CHO) cell expression system and features the RSV fusion (F) protein stabilized in its highly immunogenic prefusion (Pre-F) conformation. By maintaining the F protein in this state, the vaccine aims to elicit a robust immune response and high titers of neutralizing antibodies against critical epitopes, such as Site Ø, which are lost when the protein transitions to its postfusion form. MV-RSV-01 is administered via intramuscular injection and is intended for use in healthy adults, including the elderly population who are at high risk for severe RSV-related complications.
- Other names
- Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)Recombinant RSV vaccine (CHO cells)
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on MV-RSV-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MV-RSV-01.